CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-titration trial to study the efficacy, safety, and
pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous
candidiasis infections in patients who are refractory or intolerant to standard non
intravenous therapies.